Company: CDT
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001493152-25-006960
Chunk: 9

Company: CDT Equity Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 9
---
 issued in satisfaction of obligations the Company incurred under the Isayan Convertible Promissory Note in the principal amount of $800,000 which accrued interest at 20% per annum and was payable every six months from March 20, 2023, but was later amended by theIsayan Loan Extension Amendment pursuant to which the principal amount and accrued interest were satisfied via Shares issued to the Isayan Payees; (c) 5,690 Shares issued in satisfaction of obligations the Company incurred under the Reeves Loan Agreement in the principal amount of GBP $85,000, of which was amended by the Reeves Loan Variation Agreement; and (d) 5,690 Shares issued in satisfaction of obligations the Company incurred under the Bereika Loan Agreement in the principal amount of GBP $85,000, of which was amended by the Bereika Loan Variation Agreement.

Corporate Information

On September 22, 2023, a merger transaction (the “Business Combination”) between Conduit Pharmaceuticals Limited (“Old Conduit”), Murphy Canyon Acquisition Corp (“MURF”) and Conduit Merger Sub, Inc., a Cayman Islands exempted company and a wholly owned subsidiary of MURF (“Merger Sub”), was completed pursuant to the Agreement and Plan of Merger, dated November 8, 2022, as amended, (the “Merger Agreement”). Pursuant to the terms of the Merger Agreement, at the closing, (i) Merger Sub merged with and into Old Conduit, with Old Conduit surviving the Business Combination as a wholly-owned subsidiary of MURF, and (ii) MURF changed its name from Murphy Canyon Acquisition Corp. to Conduit Pharmaceuticals Inc.

Our principal executive offices are located at 4581 Tamiami Trail North, Suite 200, Naples, Florida 34103, and our telephone number is (646) 491-9132. Our website address is http://www.conduitpharma.com. The information contained on or otherwise accessible through our website is not part of this prospectus.

| 4 |

<div align='center'>The Offering</div>

| Shares                                            
 of Common                                         
 Stock offered by the                              
 Selling Stockholders                              |     | 5,898,705                                                                                                                                
 shares of Common Stock issuable upon the conversion of the Convertible Note, the exercise of the A.G.P Warrants, and issuance of         
 shares pursuant to the Sarborg Services Agreement, Heilbron Consulting Agreement, Isayan Loan Agreements, Reeves Loan Agreements,        
 and Bere